NCT01665768View on ClinicalTrials.gov

Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 31, 2017

Study Completion Date

August 31, 2020

Conditions
CD20+, B-cell LymphomasMantle Cell LymphomaNon-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL)Transformed Lymphoma/DLBCL/PMBCLHodgkin's DiseaseGray Zone Lymphoma
Interventions
DRUG

Everolimus

The initial dose of everolimus will be 2.5mg orally daily for a total of one year to maintain a target trough concentration between 3-15 ng/mL.

BIOLOGICAL

Rituximab

375mg/m2 day +1 and then every 90 days for 1 year (a total of 4 infusions)

Trial Locations (1)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER